Has Benjamin Downie, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,932 in general payments to Benjamin Downie, MD across 756 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Benjamin Downie, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Benjamin Downie, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Benjamin Downie, MD

Medical Oncology · Clovis, NMNPI 1477765550

Payments from drug & device makers

$13,932in general payments, 2019–2025

Across 756 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$1K
Johnson & Johnson$1K
Novartis$877
AstraZeneca$757
Merck$755
Amgen$680
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	63	$1,127
Johnson & Johnson	71	$1,041
Novartis	44	$877
AstraZeneca(2 entities)	41	$757
Merck	40	$755
Amgen	38	$680
Bristol Myers Squibb	30	$599
Sanofi	30	$528
Pfizer	35	$459
Puma Biotechnology, Inc.	20	$406
Astellas Pharma US Inc	16	$383
Lilly USA, LLC	17	$374
Incyte Corporation	17	$346
Genentech USA, Inc.	23	$334
Bayer	18	$296
Gilead(2 entities)	14	$261
Eisai Inc.	13	$238
Seagen Inc.	13	$232
GSK	14	$227
Regeneron Healthcare Solutions, Inc.	10	$204
Takeda Pharmaceuticals U.S.A., Inc.	7	$203
Beigene USA, Inc.	8	$159
Karyopharm Therapeutics Inc.	7	$153
Ipsen Biopharmaceuticals, Inc	8	$148
Taiho Oncology, Inc.	8	$145
AbbVie	6	$141
Morphosys, US Inc.	7	$127
AVEO Pharmaceuticals, Inc.	6	$107
Boston Scientific	1	$106
Foundation Medicine, Inc.	7	$105
EMD Serono, Inc.	6	$104
Pharmacyclics LLC, An Abbvie Company	6	$103
Dova Pharmaceuticals	6	$96
Heron Therapeutics, Inc.	4	$94
Teva Pharmaceuticals USA, Inc.	5	$94
Mirati Therapeutics, Inc.	4	$90
Jazz Pharmaceuticals Inc.	4	$90
Stryker	1	$83
Boehringer Ingelheim	4	$82
Sobi, Inc	4	$79
ADC Therapeutics America, Inc.	4	$79
Daiichi Sankyo Inc.	4	$76
Organon	5	$72
Servier Pharmaceuticals LLC	4	$72
Octapharma USA, Inc.	2	$71
Rigel Pharmaceuticals, Inc.	4	$71
Blueprint Medicines Corporation	4	$70
Pharmaessentia USA Corporation	2	$69
G1 Therapeutics, Inc.	3	$67
Stemline Therapeutics Inc.	3	$66
AMAG Pharmaceuticals, Inc.	5	$66
Myriad Genetic Laboratories, Inc.	4	$63
Exelixis Inc.	4	$63
CTI Biopharma Corp.	3	$55
GE HealthCare	2	$49
Kyowa Kirin, Inc.	2	$38
Macrogenics, Inc.	2	$32
Genmab U.S., Inc.	1	$29
Immunocore Limited	2	$28
Secura Bio, Inc.	1	$27

How this compares

Too few medical oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$369,443

Medicare patients

531

Services billed

20,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Clovis

Katherine SanchezAlbuquerque$654K
Atul KumarAlbuquerque$327K
Annette FontaineAlbuquerque$298K
Ronald KubicaAlbuquerque$191K
Richard GiudiceAlbuquerque$18K
Constance WashLas Cruces$9K
Sofia Palacio CardenasAlbuquerque$9K
Malcolm PurdyAlbuquerque$7K
Amyn AlidinaAlbuquerque$6K
Kira MacdougallSanta Fe$3K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →